The investor presentation reaffirms existing guidance and highlights strong sleep therapy growth and a clean balance sheet. The new buyback authorization signals management confidence. Monitor upcoming quarterly filings for execution against the $316M revenue and $67M EBITDA guidance midpoints.
Price Chart
Executive Summary
VieMed Healthcare filed an 8-K with an investor presentation (June 2026) highlighting record FY2025 results ($270M net revenue, $61M Adjusted EBITDA, $28M FCF) and continued Q1 2026 momentum ($75.4M net revenue, +28% YoY). The presentation reaffirms FY2026 guidance of $312M-$320M net revenue and $65M-$69M Adjusted EBITDA, and announces a new share repurchase program for up to 5% of shares outstanding. The filing is a routine investor update with no new material financial disclosures beyond previously reported results.
Key Facts
- FY2025 net revenue of $270M, Adjusted EBITDA of $61M, free cash flow of $28M
- Q1 2026 net revenue of $75.4M (+28% YoY), Adjusted EBITDA of $14.3M (+12% YoY)
- FY2026 guidance: net revenue $312M-$320M, Adjusted EBITDA $65M-$69M
- New share repurchase program authorized for up to 5% of shares outstanding
- Zero net debt, $46M credit facility availability as of March 31, 2026
- Sleep therapy patients increased 57% YoY in Q1 2026; vent patients up 2% YoY
Financial Impact
No new financial data beyond previously reported Q1 2026 results; FY2026 guidance midpoint implies ~17% net revenue growth and ~9% Adjusted EBITDA growth vs FY2025
Risk Factors
- Gross margin compression from service mix shift (57.5% in FY2025 vs 61.6% in FY2023)
- Vent patient growth slowing to 2% YoY in Q1 2026
- NCD implementation adds administrative complexity in near term
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001729149-26-000032 |
| Document: vmd-20260602.htm | 0001729149-26-000032 |
| Document: 0001729149-26-000032-index-headers.html | 0001729149-26-000032 |
| Document: 0001729149-26-000032-index.html | 0001729149-26-000032 |
| Document: 0001729149-26-000032.txt | 0001729149-26-000032 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | SC 13D/A | $8.91 $9.11 | ▼ −2.24% | ▼ −2.99% | $9.73 (−9.20%) |
Aug 20, 2026 9w ago | 8-K | $8.85 $9.09 | ▲ +2.71% | ▲ +3.01% | $9.73 (+9.94%) |
Aug 3, 2026 12w ago | 8-K | $9.84 $9.82 | ▼ −0.15% | ▲ +0.05% | $9.73 (−1.07%) |
Jun 4, 2026 20w ago | 8-K | $9.97 $9.92 | ▼ −0.50% | ▼ −0.73% | $9.73 (−2.41%) |
Jun 2, 2026 20w ago | 8-K | $9.56 $9.84 | ▲ +2.93% | ▲ +2.53% | $9.73 (+1.78%) |
May 5, 2026 24w ago | 8-K | $8.52 $8.52 | · 0.00% | ▲ +0.33% | $9.73 (+14.27%) |
Mar 4, 2026 33w ago | 8-K | $8.40 $8.78 | ▲ +4.52% | ▲ +5.84% | $9.73 (+15.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers